GC Corp.'s Form 4 filing
Artiva Biotherapeutics, Inc. (ARTV) · filed Jul 22, 2024
- Accession no.
- 0001415889-24-019907
- Filed
- Jul 22, 2024, 8:25 PM ET
- Trade date
- Jul 22, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market purchases total $25.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| GC Corp.CIK 0001931382 | 10% Owner |
| GC Cell CorpCIK 0001931891 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 22, 2024 | Common Stock | CConversionAcquired | +667,185 | –F1 | – | 1,016,022 | Direct | |
| Jul 22, 2024 | Common Stock | CConversionAcquired | +330,095 | –F1 | – | 1,346,117 | Direct | |
| Jul 22, 2024 | Common Stock | JOtherAcquired | +294,117 | $10.20 | +$2,999,993.4 | 1,640,234 | Direct | |
| Jul 22, 2024 | Common Stock | PPurchaseAcquired | +1,666,666 | $12.00 | +$19,999,992 | 3,306,900 | Direct | |
| Jul 22, 2024 | Common Stock | CConversionAcquired | +292,791 | –F1 | – | 525,349 | Indirect | |
| Jul 22, 2024 | Common Stock | CConversionAcquired | +62,181 | –F1 | – | 587,530 | Indirect | |
| Jul 22, 2024 | Common Stock | JOtherAcquired | +256,316 | $10.20 | +$2,614,423.2 | 843,846 | Indirect | |
| Jul 22, 2024 | Common Stock | PPurchaseAcquired | +416,666 | $12.00 | +$4,999,992 | 1,260,512 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 22, 2024 | Common Stock | CConversionDisposed | −667,185 | –F1 | – | 0 | Direct | |
| Jul 22, 2024 | Common Stock | CConversionDisposed | −330,095 | –F1 | – | 0 | Direct | |
| Jul 22, 2024 | Common Stock | CConversionDisposed | −292,791 | –F1 | – | 0 | Indirect | |
| Jul 22, 2024 | Common Stock | CConversionDisposed | −62,181 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.